Brief: Skye Bioscience Surpasses 50% Patient Enrollment In Phase 2 Obesity Study Of Differentiated CB1 Inhibitor
14/11/2024 12:23
Nov 14 (Reuters) - Skye Bioscience Inc SKYE.O :
* SKYE BIOSCIENCE SURPASSES 50% PATIENT ENROLLMENT IN PHASE
2
OBESITY STUDY OF DIFFERENTIATED CB1 INHIBITOR
* SKYE BIOSCIENCE INC - EXPECTS INTERIM DATA FOR CBEYOND
PHASE 2
TRIAL IN Q2 2025
Source text: urn:newsml:reuters.com:*:nGNXbSSgY1
Further company coverage: SKYE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsRCS - Redx Pharma Limited - Redx to Present Poster on RXC008 at UEG Week
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
Brief: Skye Bioscience Says John Sharp Resigns As CFO - SEC Filing
Brief: Skye Bioscience - Enters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments Iii - SEC Filing
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM